Related Experiment Video

Updated: Jun 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Lipid-lowering drugs and heart failure: where do we go after the statin trials?

Timo E Strandberg1

  • 1Institute of Health Sciences/Geriatrics, University of Oulu, Oulu University Hospital, Oulu, Finland. timo.strandberg@oulu.fi

Current Opinion in Cardiology
|June 16, 2010
PubMed

Insights

Statins help prevent heart failure by addressing factors like myocardial damage. However, starting statins in patients with existing heart failure does not improve outcomes, though stopping them is not recommended.

Area of Science:

  • Cardiology
  • Lipid Metabolism
  • Heart Failure Research

Background:

  • Heart failure poses a significant health burden, particularly in aging populations.
  • Statins (HMG-CoA reductase inhibitors) are known to prevent heart failure causes like myocardial damage and ischemia.
  • The efficacy of statins and low-density lipoprotein (LDL) lowering in established heart failure patients remains debated, with less focus on other dyslipidemias like low high-density lipoprotein (HDL) and high triglycerides.

Purpose of the Study:

  • To review the current evidence on the benefits and limitations of statin therapy in heart failure.
  • To explore the role of dyslipidemia, including HDL and triglycerides, in heart failure.
  • To evaluate the impact of initiating or continuing statin treatment in different stages of heart failure.

Main Methods:

  • Review of randomized trials and observational studies on statin use in coronary artery disease (CAD) and heart failure.
  • Analysis of data linking lipid profiles (LDL, HDL, triglycerides) to heart failure prognosis.
  • Synthesis of findings regarding the timing of statin initiation and its effect on patient outcomes.

Main Results:

  • Statin treatment effectively prevents heart failure in patients with CAD or at high risk.
  • Intensive statin regimens show greater benefit than standard doses in prevention.
  • Initiating statins in patients with established or advanced heart failure has not improved prognosis, but statins are not harmful and may reduce complications.
  • HDL metabolism variables are linked to heart failure, but evidence for HDL- or triglyceride-modifying therapies is limited.

Conclusions:

  • Statins are crucial for preventing or delaying heart failure onset.
  • Initiating statins in patients with established heart failure does not improve prognosis.
  • Discontinuation of statins is not advised upon heart failure diagnosis.
  • Combined therapies targeting both LDL and HDL may offer enhanced heart failure prevention strategies.
Abstract

More Related Videos

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...